by Raynovich Rod | Aug 6, 2019 | Clinical Diagnostics and Tools
8/10/19…XBI up 1.8% to $84.04 for 5 days, QQQ up 1.9% to $185.81 over 5 days.A good week for life science stocks with following stocks near 52 week highs: BDX BIO DHR GH HOLX NVTA 8/8/19 9:45a EDT Life Science Movers…Stocks to Watch…XBI up 0.61% to...
by Raynovich Rod | Jun 24, 2019 | Biopharmaceuticals, Macro
Update-2… 6/27 2p EDT…Good day for gene therapy stocks My longs CRSP and MGTX are up. Looking better all across the screen in biopharma. Added to ABBV and XNCR yesterday. XBI up but still under $86. Update-1… Another Big Deal in Biotech in a weak...
by Raynovich Rod | Jun 17, 2019 | Biopharmaceuticals
Update-3. Red screen day, post after close, macro intervening again. BMY/CELG delayed on Otezla divestiture. Update -2 …Week Ending 6/21-Biotech stocks up for the week but momentum easing. XBI up 1.2% to $87.26, off Wednesday highs. IBB up .2.2% to $109.45 QQQ...
by Raynovich Rod | Mar 29, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-4. 4/3 11:45A… Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3 4/2/19… Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91% NTLA 4.9% MGTX up 4.6%,...
by Raynovich Rod | Aug 31, 2018 | Biopharmaceuticals
9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down...
by Raynovich Rod | Jul 22, 2018 | Biopharmaceuticals
7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9% to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock...
by Raynovich Rod | Jun 19, 2018 | Biopharmaceuticals, Clinical Diagnostics and Tools
Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50...
by Raynovich Rod | Jun 8, 2018 | Biopharmaceuticals
ASCO 2018 Rally Part 2: Traders Take Profits on Nice Gains Biotech Indices and ETFs Show Gains YTD: FBIOX up 8% YTD, IBB up 3.13%, XBI up 9.34% The ASCO 2018 biotech rally was almost according to the script-nice gains leading up to the meeting followed by momentum...
by Raynovich Rod | Jun 6, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
ASCO 2018 Biotech Rally: Biotechs, Techs, and Semis Lead Market Higher Mid-Caps show huge gains but with high volatility. FBT at 142.91, IBB lagging at $110.52, XBI leading at $97.77 IWC Micro-Cap ETF breaking out up 11% YTD. Healthcare (XLV) comes to life lately up...
by Raynovich Rod | Jan 12, 2018 | Biopharmaceuticals
J.Morgan Healthcare Conference: Companies to Watch We are still reviewing 2018 J.P.Morgan Healthcare presentations for inclusion in our portfolio but here are two longer term opportunities to track for milestones and growth: Accelerate Diagnostics and Denali...
